Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road Room 3033, Atlanta, GA 30322, USA; Department of Medicine, Morehouse School of Medicine, 720 Westview Dr SW, Atlanta, GA 30310, USA.
Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road Room 3033, Atlanta, GA 30322, USA.
Infect Dis Clin North Am. 2018 Jun;32(2):323-345. doi: 10.1016/j.idc.2018.02.014.
An estimated 30% of Americans with hepatitis C virus (HCV) pass through a jail or prison annually. One in 7 incarcerated persons is viremic. Screening and treatment is cost-effective and beneficial to society as a whole. Yet at current (2018) levels of funding for HCV management, prisons are not aggressively seeking cases; few incarcerated persons with HCV actually receive treatment. This article explores barriers to screening for and treating hepatitis C in state prisons, and ways that states may overcome these barriers, such as nominal pricing. While high prices for direct-acting antivirals discourage treatment, potential strategies exist to lower prices.
据估计，每年有 30%的美国丙型肝炎病毒（HCV）感染者会进出监狱或看守所。每 7 名被监禁者中就有 1 人呈病毒血症。对 HCV 进行筛查和治疗具有成本效益，并且对整个社会有益。然而，目前（2018 年）用于 HCV 管理的资金水平，监狱并没有积极地寻找病例；实际上，只有少数 HCV 感染者接受了治疗。本文探讨了在州立监狱中筛查和治疗丙型肝炎的障碍，以及各州克服这些障碍的方法，例如象征性定价。虽然直接作用抗病毒药物的高价格阻碍了治疗，但存在降低价格的潜在策略。
